Why GLP-1 Drug Lawsuits Are Being Filed as an MDL GLP-1 drug injury claims are particularly well-suited to an MDL structure because the injuries plaintiffs have suffered vary significantly from one individual to the next
Amylins Physiological Control of Gastric Emptying: the Established Baseline To judge whether cagrilintide slows the stomach, we first need a clear picture of what amylin does in its native, physiological form because this is the part of the story that rests on solid ground
Oral supplements of glutathione are available both over-the-counter and with a prescription, although the digestion process may break down pure glutathione and repurpose it for other uses
Refrigeration is recommended for extended storage
Reports like UABs could further bolster claims of inadequate guidance on safe use and dosing
If metformin at a maximum tolerated dose does not achieve the HbA1c target after 3 months, add a second oral agent (a sulfonylurea [SU], thiazolidinedione [TZD], dipeptidyl peptidase 4 [DPP-4] inhibitor, or sodium-glucose cotransporter-2 [SGLT2] inhibitor), a glucagon-like peptide-1 (GLP-1) receptor agonist, or a basal insulin ( TABLE 2 )
